Carcinoembryonic antigen (CEA) is synthesized during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Anti-CEA is reportedly useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).
Applications
Suitable for use in ELISA. Other applications not tested.
Recommended Dilutions
Optimal dilutions to be determined by the researcher.
Matched Pair
Suitable for use as the capture or solid phase antibody. Matched to C1299-87E, C1299-87F or C1299-87U, C1299-87H as the detection or conjugate (label) antibody. Also suitable for use as the detection or conjugate (label) antibody. Matched to C1299-87F, C1299-87H, C1299-87U as the capture or solid phase antibody.
Affinity Constant
1x10e9L/mole
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Carcinoembryonic Antigen purified from human tumor
Form
Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.
Purity
Purified by Protein A affinity chromatography from ascites.
Specificity
Recognizes human Carcinoembryonic Antigen.
TDS
NCBI
UniProt
Tech Support
Customer Service
